134 related articles for article (PubMed ID: 26211748)
1. [Are there cardiovascular adverse effects of inhaled anticholinergics?].
Nagy LB
Orv Hetil; 2015 Aug; 156(31):1246-52. PubMed ID: 26211748
[TBL] [Abstract][Full Text] [Related]
2. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence.
Salpeter SR
Drugs; 2009 Oct; 69(15):2025-33. PubMed ID: 19791824
[TBL] [Abstract][Full Text] [Related]
3. The use of inhaled anticholinergics in chronic obstructive pulmonary disease: is there cause for concern of cardiovascular safety?
McIvor RA
Pol Arch Med Wewn; 2009 Nov; 119(11):697-8. PubMed ID: 19920792
[No Abstract] [Full Text] [Related]
4. [Anticholinergics and their cardiovascular effects--between fear and reality].
Mihălţan F; Ulmeanu R
Pneumologia; 2010; 59(2):107-8. PubMed ID: 20695368
[No Abstract] [Full Text] [Related]
5. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Singh S; Loke YK; Furberg CD
JAMA; 2008 Sep; 300(12):1439-50. PubMed ID: 18812535
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease.
Gershon A; Croxford R; Calzavara A; To T; Stanbrook MB; Upshur R; Stukel TA
JAMA Intern Med; 2013 Jul; 173(13):1175-85. PubMed ID: 23689820
[TBL] [Abstract][Full Text] [Related]
7. Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.
Singh S; Loke YK; Enright P; Furberg CD
Postgrad Med J; 2014 Apr; 90(1062):205-7. PubMed ID: 24643260
[TBL] [Abstract][Full Text] [Related]
8. [Pneumology. Should we fear inhaled anticholinergic bronchodilators?].
Rochat T; Janssens JP
Rev Med Suisse; 2009 Jan; 5(186):135-7. PubMed ID: 19238933
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.
Cooper CB; Anzueto A; Decramer M; Celli B; Tashkin DP; Leimer I; Kesten S
Int J Chron Obstruct Pulmon Dis; 2011; 6():269-75. PubMed ID: 21845038
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD.
Hilleman DE; Malesker MA; Morrow LE; Schuller D
Int J Chron Obstruct Pulmon Dis; 2009; 4():253-63. PubMed ID: 19657399
[TBL] [Abstract][Full Text] [Related]
11. The cardiovascular risk of tiotropium: is it real?
Cazzola M; Calzetta L; Matera MG
Expert Opin Drug Saf; 2010 Sep; 9(5):783-92. PubMed ID: 20565229
[TBL] [Abstract][Full Text] [Related]
12. Comparison of risk of neurovascular and cardiovascular side effects between tiotropium and other anticholinergic agents.
Alzayer R; Hughes J; Parsons R; Lee YP
Qual Prim Care; 2010; 18(3):189-99. PubMed ID: 20659403
[TBL] [Abstract][Full Text] [Related]
13. [Safety of tiotropium therapy in chronic obstructive lung diseases (COPD)].
Osztovits J; Fehér J
Orv Hetil; 2010 May; 151(18):749-50. PubMed ID: 20410002
[No Abstract] [Full Text] [Related]
14. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications.
Singh S; Loke YK; Enright P; Furberg CD
Thorax; 2013 Jan; 68(1):114-6. PubMed ID: 22764216
[TBL] [Abstract][Full Text] [Related]
15. How safe are anticholinergics in patients with COPD?
Hew MJ; Sestini P; Irving LB
Med J Aust; 2009 May; 190(9):468-9. PubMed ID: 19413514
[TBL] [Abstract][Full Text] [Related]
16. Tiotropium: a potential replacement for ipratropium in patients with COPD.
Shukla VK
Issues Emerg Health Technol; 2002 Jul; (35):1-4. PubMed ID: 12195603
[TBL] [Abstract][Full Text] [Related]
17. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.
Hodgin KE; Maloney JP
JAMA; 2009 Mar; 301(12):1224; author reply 1225-6. PubMed ID: 19318647
[No Abstract] [Full Text] [Related]
18. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.
Kesten S; Leimer I; Jara M
JAMA; 2009 Mar; 301(12):1224; author reply 1225-6. PubMed ID: 19318648
[No Abstract] [Full Text] [Related]
19. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.
Oba Y
JAMA; 2009 Mar; 301(12):1223; author reply 1225-6. PubMed ID: 19318646
[No Abstract] [Full Text] [Related]
20. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.
Covelli HD
JAMA; 2009 Mar; 301(12):1223; author reply 1225-6. PubMed ID: 19318645
[No Abstract] [Full Text] [Related]
[Next] [New Search]
